Immune Checkpoint Inhibitors
Overexpression of PD-L1 has been observed in many carcinomas including lung, urinary bladder, gastroesphageal junction, Squamous Cell Carcinoma of the Head and Neck (SCCHN), cervical and melanoma
Tumor PD-L1 expression levels have been shown to be a predictive marker with response to several anti-PD1 antibodies1,2
1. Kim, JW and Eder, JP, Prospects for Targeting PD-1 and PD-L1 in Various Tumor Types. Available on the website of the Cancer Network. (http://www.cancernetwork.com/ oncology-journal/prospects-targeting-pd-1-and-pd-l1- various-tumor-types). Accessed July 8, 2015.
2. Garon, EB et al., Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer. N Engl J Med 2015; 372:2018-28.